Autism Parent's Perspective: 8 years of Bumetanide Use - Peter Lloyd Thomas MBA @Synchrony2020

Peter has a Master’s degree in Engineering from Imperial College, London and an MBA from INSEAD in Fontainebleau, France. Peter comes from a family of doctors, who were all taught that Autism is untreatable. Peter discovered after trialing Bumetanide in 2012 that his son’s autism does respond to drug therapy. He then developed a personalized polytherapy, the autism Polypill, to treat his son’s specific phenotype.

He shares the published research and his own insights via his blog Epiphany ASD, with parents, doctors and even some researchers: https://epiphanyasd.blogspot.com/

Peter is a member of the Scientific Advisory Board of the Pitt Hopkins Research Foundation.

#autismparents #autismtreatments #science #scientific #treatments #therapies


This talk was part of Synchrony 2020 Online Symposium - 'From Bench to Biopharma', organised by the The BRAIN Foundation in partnership with UC Davis MIND Institute and CalTech.

For more Synchrony 2020 talks and highlights:    • Synchrony Symposium 2020 - From Bench...  

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

Synchrony https://synchronysymposium.com/ is the first and only international symposium on translational research in #autism, that brings together academia, #biotech, pharmaceutical companies and #venture partners from around the world with the mission to improve health and quality of life of people with #autismspectrumdisorder.

🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠 🧠

The BRAIN Foundation https://brainfoundation.org/ is a 501c(3) non-profit. The founders of BRAIN envision a world where every child and adult on the autism spectrum is healthy, participates fully in education and employment, and has a better quality of life. It aims to catalyze research that results in evidence-based interventions for the disabilities associated with autism, and also results in better medical standard of care.

To accomplish this, it funds impactful research through #philanthropy and our network of partners in the venture, corporate, and grassroots community.